Hospital Universitario Puerta De Hierro De Majadahonda

At Hospital Universitario Puerta De Hierro De Majadahonda, researchers are exploring new treatments for focal segmental glomerulosclerosis. The study aims to assess how the investigational agent DMX-200 impacts kidney function markers such as urine protein‑to‑creatinine ratio and estimated glomerular filtration rate, while also monitoring long‑term safety in patients already receiving standard blood‑pressure therapy.

• Evaluation of renal biomarkers
• Assessment of treatment tolerability over time
• Integration with standard ARB therapy

This work reflects the site’s commitment to advancing care for rare kidney disorders within its broader oncology focus.

The oncology department conducts a range of studies targeting solid tumors, including high‑risk hepatocellular carcinoma, locally advanced or metastatic non‑small cell lung cancer, urothelial carcinoma, and cancers driven by the MAPK pathway. Trials compare innovative combinations such as a checkpoint inhibitor with anti‑angiogenic therapy, HER‑2 directed antibody‑drug conjugates, and KRAS‑targeted agents against standard treatments or surveillance, aiming to improve progression‑free and recurrence‑free survival.

• Regorafenib‑pembrolizumab versus locoregional therapy in HCC
• Atezolizumab plus bevacizumab as adjuvant therapy after resection
• Disitamab vedotin combined with pembrolizumab for HER2‑positive urothelial cancer
• Adagrasib added to chemotherapy and pembrolizumab for KRAS‑mutated NSCLC
• DCC‑3084 monotherapy across multiple solid tumor types

With 41 investigators and six active trials, the site leverages its expertise to bring cutting‑edge therapies to patients across Madrid and the wider European region.